The Quantellect read.As of Nov 20, 2026, 6 active firms cover Arcturus Therapeutics Holdings Inc: 6 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $19.00 to $27.00, a moderate spread. The average target of $22.17 sits 192% above the current $7.60. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near -53% this year and 10% next, consensus EPS building from about $-0.83 next quarter toward $-3.27 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 active firms
Buy
Strong Buy00%
Buy6100%
Neutral00%
Sell00%
Strong Sell00%
Based on 6 active firms as of Nov 20, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$22.17
+191.7% upside
Average target across 6 active firms as of Nov 20, 2026 vs $7.60 current
Highest Target$27.00
Average Target$22.17
Lowest Target$19.00
Detailed analyst forecasts for ARCT
Showing 1–7 of 7 named analysts shown · 6 active firms in the rating projection
As of Nov 20, 2026, 6 of 6 active firms rate ARCT a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ARCT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.83
Range $-0.95 – $-0.76 · 4 analysts · -12% YoY
Next period, 4 analysts expect Arcturus Therapeutics Holdings Inc to earn $-0.83 a share (range $-0.95 – $-0.76), versus $-0.95 a year earlier. Full-year consensus is $-2.88, growing to $-3.27 the year after.
REVENUE · NEXT QUARTER
$1.9M
Range $600.0K – $3.8M · 4 analysts · -61% YoY
Revenue is expected to reach $1.9M (range $600.0K – $3.8M), -61.0% year-over-year. Full-year consensus is $28.0M, rising to $30.0M next year.
Top analysts covering Arcturus Therapeutics Holdings Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ARCT.
#1
Mayank Mamtani
B. Riley Securities · Rank #36
Buy
$22.00+189.5% to target
Overall win rate
49%
+ Follow
#2
Andrew Fein
HC Wainwright & Co. · Rank #73
Neutral
$9.00+18.4% to target
Overall win rate
45%
+ Follow
#3
Ed Arce
HC Wainwright & Co. · Rank #168
Buy
$60.00+689.5% to target
Overall win rate
44%
+ Follow
#4
Greg Harrison
Scotiabank · Rank #223
Buy
$35.00+360.5% to target
Overall win rate
38%
+ Follow
#5
PS
Pete Stavropoulos
Cantor Fitzgerald · Rank #300
Buy
No targeton ARCT
Overall win rate
35%
+ Follow
ARCT stock forecast FAQ
What is ARCT's average 12-month price target?+
The 6 active firms with a live target average $22.17 for Arcturus Therapeutics Holdings Inc over the next 12 months, ranging from a $27.00 high to a $19.00 low, as of Nov 20, 2026.
Is ARCT stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 6 active firms as of Nov 20, 2026, 6 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for ARCT?+
The Street-high target is $27.00 (Freedom Broker), and the Street-low is $19.00 (Leerink Partners). The average of all 6 active-firm targets is $22.17.
How many active Wall Street firms cover ARCT?+
6 active firms have a recognized rating on Arcturus Therapeutics Holdings Inc as of Nov 20, 2026, and 6 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ARCT?+
Among analysts who currently cover ARCT, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #36). Their current call is Buy with a $22.00 target.
What is Arcturus Therapeutics Holdings Inc's projected EPS for next quarter?+
The consensus estimate is $-0.83 per share (range $-0.95 – $-0.76) across 4 analysts. Full-year EPS is projected at $-2.88, rising to $-3.27 the following year.
How much revenue is Arcturus Therapeutics Holdings Inc expected to report next quarter?+
Consensus revenue is $1.9M (range $600.0K – $3.8M). Full-year revenue is projected at $28.0M, growing to $30.0M next year.
Have analysts been upgrading or downgrading ARCT lately?+
As of Nov 20, 2026, 6 of 6 active firms rate ARCT a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ARCT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.